LinkedIn
WebsiteIntroduction to Applied DNA Sciences Inc.
Applied DNA Sciences Inc. (NASDAQ: APDN) is a biotechnology company specializing in DNA-based technologies for genetic medicine. The company designs, produces, and commercializes its LineaDNA™ platform—an enzymatic alternative to plasmid DNA—for applications in mRNA production, gene and cell therapy, and advanced therapeutic modalities. As of September 30, 2025, APDN shares closed at $3.78, reflecting a 27.72% decrease for the day on a trading volume of 405,759.
| Ticker | Exchange | Price (09/30/2025) | Daily Change | Volume |
|---|---|---|---|---|
| APDN | NASDAQ | $3.78 | -27.72% | 405,759 |
Corporate Structure and Experience
Founded over 20 years ago, Applied DNA Sciences utilizes expertise in polymerase chain reaction (PCR) and enzymatic DNA synthesis. Through its majority-owned subsidiary, LineaRx Inc., the company is advancing its LineaDNA™ and LineaIVT™ platforms to support nucleic acid therapies.
- Employee Count: 61 full-time employees, with a commitment to create at least 23 additional positions by 2035 under New York State's Excelsior Jobs Program.
- Board of Directors: Comprised of individuals with leadership experience across bioagriculture, zoology, and related scientific fields.
- Corporate Offices: Located at 50 Health Sciences Drive, Stony Brook, NY 11790.
DNA biotechnology by Sangharsh Lohakare
Developments and News
In August 2025, Governor Kathy Hochul announced state support via tax credits and the Long Island Investment Fund for Applied DNA Sciences to establish New York's first cGMP LinearDNA manufacturing facility on Long Island. The initiative aims to bolster production capacity for non-plasmid therapeutic DNA and to foster job creation in the life sciences corridor.
Key SEC filings this quarter include:
- 8-K filed September 29, 2025: Disclosures under Items 1.01 (material agreements), 3.02 (unregistered equity sales), 5.02 (management changes), and 8.01 (other events).
- Schedule 13G filed September 8, 2025: Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC reported beneficial ownership of 143,336 shares (9.99%).
- Schedule 13G/A filed August 14, 2025: Anson Funds Management LP, Anson Management GP LLC, and Tony Moore amended beneficial ownership to 573,538 shares (8.2%).
Financial and Strategic Analysis
While Applied DNA Sciences does not report quarterly revenues in the 8-K, the filing indicates ongoing strategic agreements and potential equity transactions. Institutional ownership disclosures reveal substantial investor interest: nearly 10% held by one group as of early September and over 8% by another in mid-August.
Strategically, the company's state-supported facility and Excelsior Jobs tax credits are intended to:
- Reduce DNA manufacturing lead times and costs.
- Enhance the safety and scalability of LineaDNA compared to plasmid methods.
- Position the company as a supplier to biopharma customers from discovery through clinical trials.
Market Position and Industry Context
Applied DNA Sciences operates in the biotechnology sector's synthetic DNA and nucleic acid manufacturing segment. Its enzymatic, cell-free approach addresses limitations of bacterial fermentation, meeting demand for:
- mRNA vaccines and therapeutics.
- Gene and cell therapy vectors.
- Supply chain authentication solutions across various industries.
Situated in Long Island's growing life sciences corridor, APDN benefits from regional research institutions and state-backed investment programs supporting innovation in DNA-based medicine.
TL;DR
- On September 30, 2025, APDN shares decreased by 27.72% to $3.78 amidst market volatility.
- SEC Form 8-K filed on September 29, 2025, disclosed new agreements, equity transactions, and management changes.
- Schedule 13G filings from September 8 and August 14, 2025, indicate two investor groups holding 9.99% and 8.2% of shares, respectively.
- State support announced in August 2025 secures tax credits for the establishment of a cGMP LinearDNA facility on Long Island, with 23 new jobs pledged by 2035.
- The facility and Excelsior Jobs Program funding aim to scale enzymatic DNA manufacturing for mRNA, gene therapy, and clinical customers.
